Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
Gynecologic Oncology|August 10, 2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neuJoan Tymon-Rosario, Eric R Siegel, Stefania Bellone, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Gynecologic Oncology Reports|May 7, 2026
Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 StatusAlexa Dzienny, Yasmin Abozenah, James Griffith, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
Gynecologic Oncology|July 1, 2020
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinomaElena Bonazzoli, Stefania Bellone, Luca Zammataro, et al.
Cancer Research Communications|March 27, 2023
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair DefectsMansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Scientific Reports|January 24, 2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanBurak Zeybek, Aranzazu Manzano, Anna Bianchi, et al.
Frontiers in Oncology|March 3, 2020
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerEmanuele Perrone, Salvatore Lopez, Burak Zeybek, et al.
Molecular Oncology|January 1, 2020
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoEmanuele Perrone, Paola Manara, Salvatore Lopez, et al.
Gynecologic Oncology|January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoChanhee Han, Blair McNamara, Stefania Bellone, et al.
Pageof 15